The OT-I microinjected model was developed by Dr. Francis Carbone of Monash Medical School and Dr. Michael Bevan of the University of Washington. The model was created by injecting the rearranged T cell receptor Valpha2-Jalpha26 (under the control of the alpha chain promoter and enhancer) and Vbeta5-Dbeta2-Jbeta2.6 (under the control of the MHC class I promoter and the Ig heavy chain enhancer) into B6 x B6.C-H2bm1 blastocysts. The resultant founders were then backcrossed to C57BL/6. Taconic received stock from Keio University in June 2001, and the mice were rederived by backcrossing to C57BL/6NTac. OT-I transgenic mice were crossed with a homozygous C57BL/6NTac Rag2 targeted mutation model (RAGN12-M), and intercrossed for homozygosity at the Rag2 allele. The model was rederived by embryo transfer and is maintained by mating of male and female mice homozygous for both the Rag2 disruption and the OT-I transgene.
Shinkai, Y, Rathbun, G, Lam, KP, Oltz, EM, Stewart, V, Mendelsohn, M, Charron, J, Datta, M, Young, F, Stall, AM, and Alt, FW. (1992) RAG-2-Deficient Mice Lack Mature Lymphocytes Owing to Inability to Initiate V(D)J Rearrangement, Cell, 68: 855-867.
Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. (1994) T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.